Efficacy of iguratimod in the treatment of patients with palindromic rheumatism ineffective to methotrexate or hydroxychloroquine
Iguratimod has demonstrated favorable efficacy and safety in the treatment of patients with PR who have not responded adequately to MTX and HCQ, which needs to be further confirmed.
Authors
- Mengjie Chen (ORCID: https://orcid.org/0000-0002-5888-0974)
- Chuanfu Zhang (ORCID: https://orcid.org/0009-0007-1525-5830)
- Qi Zhang (ORCID: https://orcid.org/0000-0003-2463-764X)
- Wenlong Wang (ORCID: https://orcid.org/0000-0003-2122-3628)
- Yongjun Cheng (ORCID: https://orcid.org/0009-0008-2886-2362)
- Guang Jin (ORCID: https://orcid.org/0009-0008-5519-3424)
- Yue Tu
Institutions
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- The First People's Hospital of Wenling (CN)
- Seventh People's Hospital of Shanghai (CN)
- Yuxian People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1613129
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.67